You've been pretty active the last few days hoops, so is this the post you are referring to:
"I don't think the NGIO spin-off or the 1:1 dividend can occur until the uplisting. Currently the NGIO shares are being held by the transfer agent. A value has not yet been determined.
For now our NGIO shares are privately held and cannot be publicly traded. Once the uplisting is complete and we know the value of the NGIO shares, we should be able to trade them, like any other stock. However, the NGIO shares may be IPO'd or spun off by some other process. I don't think that strategy has been made public.
Here's my preferred scenario. The AE-Kiromics merger experiences a level of success in treating cancer through immunotherapy. GNBT, which owns all of AE-Kiromics gets uplisted to NASDAQ. NGIO shares, which now have an assigned value are IPO'd. We original investors in GNBT received our shares for free in the 4:1 dividend process. Put your own figure on the IPO price. On 2/23/2019 Thomas Barnard assigned a value to the NGIO shares. I forget what it was, and the article is now available though prescription only.
However, for the sake of discussion, let's say that NGIO is valued at $5 per share, and comes public at that price. The GNBT investor received 1000 NGIO shares through the dividend process. The value of those shares is now $5000. The investor can sell them and make a quick 500% profit, he/she can sell a portion of those shares, can hold the shares to see how much new investors are willing to pay, or can hold the shares indefinitely. I believe this scenario is possible, but I'm sure someone will correct me if I'm wrong."
I don't think we will know of a "level of success in treating cancer" for quite some time, so that won't necessarily help, nor slow down, the IPO. I say either 1 of 2 things will happen...1 NGIO merges with Kiromic, gets a cash investment from a big investor, then goes the route of an IPO, or 2 NGIO merges with Kiromic, gets a cash investment from a big investor, purchases a shell company and goes the route of an uplist to a major exchange (like GNBT is going thru).
I would prefer to see # 1 and let's do an old fashioned IPO. The only issue is that with an IPO, the company will get scrutinized and since there really isn't any revenue (although Kiromic has some), what will the buzz be on wallstreet and will the IPO be successful. Most likely #2 will happen and maybe FUZE will still be that shell that NGIO-Kiromic can use.
As for a value, everything is a guess. We need to hear from Joe as to what the merger is going to look like to determine what % GNBT will hold of the new merger. Afterall Kiromic shareholders/executives will have a piece of the merged company. I am not going to try an guess, however I will just watch and let if play out. It will be the value it is going to be and nothing any of us can do right now to determine or benefit from it. But I do believe it will turn out extremely well.
"I don't think the NGIO spin-off or the 1:1 dividend can occur until the uplisting. Currently the NGIO shares are being held by the transfer agent. A value has not yet been determined.
For now our NGIO shares are privately held and cannot be publicly traded. Once the uplisting is complete and we know the value of the NGIO shares, we should be able to trade them, like any other stock. However, the NGIO shares may be IPO'd or spun off by some other process. I don't think that strategy has been made public.
Here's my preferred scenario. The AE-Kiromics merger experiences a level of success in treating cancer through immunotherapy. GNBT, which owns all of AE-Kiromics gets uplisted to NASDAQ. NGIO shares, which now have an assigned value are IPO'd. We original investors in GNBT received our shares for free in the 4:1 dividend process. Put your own figure on the IPO price. On 2/23/2019 Thomas Barnard assigned a value to the NGIO shares. I forget what it was, and the article is now available though prescription only.
However, for the sake of discussion, let's say that NGIO is valued at $5 per share, and comes public at that price. The GNBT investor received 1000 NGIO shares through the dividend process. The value of those shares is now $5000. The investor can sell them and make a quick 500% profit, he/she can sell a portion of those shares, can hold the shares to see how much new investors are willing to pay, or can hold the shares indefinitely. I believe this scenario is possible, but I'm sure someone will correct me if I'm wrong."
I don't think we will know of a "level of success in treating cancer" for quite some time, so that won't necessarily help, nor slow down, the IPO. I say either 1 of 2 things will happen...1 NGIO merges with Kiromic, gets a cash investment from a big investor, then goes the route of an IPO, or 2 NGIO merges with Kiromic, gets a cash investment from a big investor, purchases a shell company and goes the route of an uplist to a major exchange (like GNBT is going thru).
I would prefer to see # 1 and let's do an old fashioned IPO. The only issue is that with an IPO, the company will get scrutinized and since there really isn't any revenue (although Kiromic has some), what will the buzz be on wallstreet and will the IPO be successful. Most likely #2 will happen and maybe FUZE will still be that shell that NGIO-Kiromic can use.
As for a value, everything is a guess. We need to hear from Joe as to what the merger is going to look like to determine what % GNBT will hold of the new merger. Afterall Kiromic shareholders/executives will have a piece of the merged company. I am not going to try an guess, however I will just watch and let if play out. It will be the value it is going to be and nothing any of us can do right now to determine or benefit from it. But I do believe it will turn out extremely well.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
